Works matching IS 22969403 AND DT 2021 AND VI 6 AND IP 3
Results: 6
Front & Back Matter.
- Published in:
- Inflammatory Intestinal Diseases, 2021, v. 6, n. 3, p. 1, doi. 10.1159/000519760
- Publication type:
- Article
Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci.
- Published in:
- Inflammatory Intestinal Diseases, 2021, v. 6, n. 3, p. 154, doi. 10.1159/000518371
- By:
- Publication type:
- Article
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients.
- Published in:
- Inflammatory Intestinal Diseases, 2021, v. 6, n. 3, p. 165, doi. 10.1159/000518264
- By:
- Publication type:
- Article
Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis.
- Published in:
- Inflammatory Intestinal Diseases, 2021, v. 6, n. 3, p. 123, doi. 10.1159/000518003
- By:
- Publication type:
- Article
A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis.
- Published in:
- Inflammatory Intestinal Diseases, 2021, v. 6, n. 3, p. 140, doi. 10.1159/000517474
- By:
- Publication type:
- Article
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results.
- Published in:
- Inflammatory Intestinal Diseases, 2021, v. 6, n. 3, p. 132, doi. 10.1159/000515593
- By:
- Publication type:
- Article